公开(公告)号：EP3383378A1

公开(公告)日：2018-10-10

申请号：EP16823075.3

申请日：2016-12-01

申请人： The Procter & Gamble Company ,  The Cleveland Clinic Foundation

发明人： HAZEN, Stanley, Leon ,  GARCIA-GARCIA, Jose Carlos ,  GERBERICK, George, Franklin ,  WOS, John, August ,  STANTON, David, Thomas ,  INGLIN, Thomas, Alfred ,  REILLY, Michael ,  DEUTSCH, Angela, Jane ,  REED, Jodie, Michelle ,  CODY, David, Blair

IPC分类号： A61K31/04 ,  A61K31/095 ,  A61K31/275 ,  A61K31/26

CPC分类号： A61K31/26 ,  A61K31/04 ,  A61K31/095 ,  A61K31/145 ,  A61K31/166 ,  A61K31/216 ,  A61K31/22 ,  A61K31/27 ,  A61K31/275 ,  A61K31/325 ,  A61K31/336 ,  A61K31/351 ,  A61K31/439 ,  A61K31/4425 ,  A61K31/4453 ,  A61K31/452 ,  A61K31/5375 ,  A61K45/06 ,  C07C331/20 ,  C07D211/46 ,  C07D213/04 ,  C07D213/30 ,  C07D213/65 ,  C07D295/13 ,  C07D303/36 ,  C07D453/02 ,  Y02A50/473

摘要： The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.

公开(公告)号：EP3478276A1

公开(公告)日：2019-05-08

申请号：EP17732269.0

申请日：2017-05-31

申请人： The Procter & Gamble Company ,  The Cleveland Clinic Foundation

发明人： HAZEN, Stanley, Leon ,  GARCIA-GARCIA, Jose Carlos ,  GERBERICK, George, Franklin ,  WOS, John, August ,  GU, Xiandong ,  REILLY, Michael ,  SIVIK, Mark, Robert ,  REED, Jodie, Michelle ,  CODY, David, Blair

IPC分类号： A61K31/04 ,  A61K31/275 ,  A61K31/14 ,  C07C211/63 ,  C07C215/40 ,  C07C217/40 ,  C07C229/12 ,  C07C229/30 ,  A61K31/205

公开(公告)号：EP3383376A1

公开(公告)日：2018-10-10

申请号：EP16819754.9

申请日：2016-12-01

申请人： The Procter & Gamble Company ,  The Cleveland Clinic Foundation

发明人： HAZEN, Stanley, Leon ,  GARCIA-GARCIA, Jose Carlos ,  GERBERICK, George, Franklin ,  WOS, John, August ,  STANTON, David, Thomas ,  INGLIN, Thomas, Alfred ,  REILLY, Michael ,  DEUTSCH, Angela, Jane ,  REED, Jodie, Michelle ,  CODY, David, Blair

IPC分类号： A61K31/04 ,  A61K31/095 ,  A61K31/275 ,  A61K31/26

CPC分类号： A61K31/26 ,  A61K31/04 ,  A61K31/095 ,  A61K31/145 ,  A61K31/166 ,  A61K31/216 ,  A61K31/22 ,  A61K31/27 ,  A61K31/275 ,  A61K31/325 ,  A61K31/336 ,  A61K31/351 ,  A61K31/439 ,  A61K31/4425 ,  A61K31/4453 ,  A61K31/452 ,  A61K31/5375 ,  A61K45/06 ,  C07C331/20 ,  C07D211/46 ,  C07D213/04 ,  C07D213/30 ,  C07D213/65 ,  C07D295/13 ,  C07D303/36 ,  C07D453/02 ,  Y02A50/473

摘要： The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.

公开(公告)号：EP2516650B1

公开(公告)日：2014-09-17

申请号：EP10803687.2

申请日：2010-12-21

申请人： The Procter & Gamble Company

发明人： SAUNDERS, Charles, Winston ,  XU, Jun ,  GREEN, Phillip, Richard ,  CODY, David, Blair ,  KHAMBATTA, Zubin, Sarosh

IPC分类号： C12N15/70 ,  C12P7/64 ,  C12N15/52 ,  C12N9/10 ,  C12N9/88 ,  C12N9/02

CPC分类号： C12N9/1029 ,  C12N9/0008 ,  C12N9/88 ,  C12N15/70 ,  C12P7/6409 ,  C12Y102/04004 ,  C12Y203/0118 ,  C12Y203/01182 ,  C12Y403/01019

公开(公告)号：EP2516650A1

公开(公告)日：2012-10-31

申请号：EP10803687.2

申请日：2010-12-21

申请人： The Procter & Gamble Company

发明人： SAUNDERS, Charles, Winston ,  XU, Jun ,  GREEN, Phillip, Richard ,  CODY, David, Blair ,  KHAMBATTA, Zubin, Sarosh

IPC分类号： C12N15/70 ,  C12P7/64 ,  C12N15/52 ,  C12N9/10 ,  C12N9/88 ,  C12N9/02

CPC分类号： C12N9/1029 ,  C12N9/0008 ,  C12N9/88 ,  C12N15/70 ,  C12P7/6409 ,  C12Y102/04004 ,  C12Y203/0118 ,  C12Y203/01182 ,  C12Y403/01019

摘要： A method for producing anteiso fatty acid is provided. The method comprises culturing a cell comprising at least one exogenous or overexpressed polynucleotide comprising a nucleic acid sequence encoding a polypeptide that catalyzes at least one of the following reactions: conversion of pyruvate to citramalate; conversion of citramalate to citraconate; conversion of citraconate to β-methyl-D-malate; conversion of β-methyl-D-malate to 2-oxobutanoate; or conversion of threonine to 2-oxobutanoate, under conditions allowing expression of the polynucleotide(s) and production of anteiso fatty acid. Optionally the cell further comprises at least one exogenous or overexpressed polynucleotide comprising a nucleic acid sequence encoding a polypeptide that catalyzes conversion of 2-oxobutanoate to 2-aceto-2-hydroxy-butyrate, conversion of 2-aceto-2-hydroxy-butyrate to 2,3-dihydroxy-3-methylvalerate, and/or conversion of 2,3-dihydroxy-3-methylvalerate to α-keto-3-methylvalerate. A cell that produces anteiso fatty acid and a method of using the cell to produce anteiso fatty acid also are provided.